Elekta AB stock (SE0000163628): SB1 Markets trims price target while keeping Neutral stance

On 06/01/2026, Elekta AB shares on Nasdaq Stockholm traded around the mid-50s SEK level, close to a recent closing price of SEK 53.70, while Norwegian broker SB1 Markets reiterated its Neutral rating on the Swedish radiation-therapy specialist but reduced its price target to SEK 57 from SEK 61, according to MarketScreener as of 05/29/2026. On its home market in Sweden, this fresh analyst update adds to the ongoing debate about Elekta AB’s medium-term growth prospects and margin profile within the domestic Nasdaq Stockholm healthcare universe.

According to MarketScreener data as of 05/29/2026, Elekta AB’s average analyst price target stands around SEK 60.50, compared with the SB1 Markets target of SEK 57, highlighting a somewhat more cautious stance by the Norwegian broker versus the broader analyst community. The stock had a quoted last close of SEK 53.70 on Nasdaq Stockholm on 05/29/2026, placing the SB1 Markets target modestly above the prevailing market price and the consensus target somewhat higher still, based on the same MarketScreener overview.

The SB1 Markets note cited by MarketScreener on 05/29/2026 flags that Elekta AB’s sales growth needs to improve, reinforcing a narrative that top-line momentum remains a key focus for investors in the Swedish medtech company. SB1 Markets therefore kept its recommendation at Neutral while adjusting the target down to SEK 57, indicating that the broker does not see sufficient evidence at this point to support a higher valuation multiple compared with earlier expectations.

Alongside rating commentary, positioning data have also shifted: Schonfeld Strategic Advisors reduced its disclosed short position in Elekta AB to below 0.50 percent of share capital, meaning the firm is no longer listed as a public short seller in the stock as of a MarketScreener report dated 05/29/2026. While this change does not represent a directional recommendation, it marginally alters the balance between bearish and non-bearish speculative positions in the Swedish name.

In Sweden’s broader equity context, Elekta AB is also on the radar of Nordic brokers for portfolio allocation decisions. Pareto, for example, added Elekta AB to a refreshed Swedish portfolio for June 2026, according to a MarketScreener article dated 05/29/2026, which discussed Swedish small and mid-cap selections and highlighted Elekta AB as a position with an improved setup into its FY 2026 financial year. The report noted that Elekta AB shares had previously been punished for operational discipline and execution issues but were seen by Pareto as better placed for a cleaner FY 2026, though without classifying the stock as a high-conviction outperformer.

From a domestic Swedish trading perspective, the combination of a Neutral reiteration from SB1 Markets, a modest reduction in the price target, the end of a disclosed short position by Schonfeld Strategic Advisors, and inclusion in a broker model portfolio provides local investors in Nasdaq Stockholm names with several incremental data points on Elekta AB as of late May 2026. For German-speaking investors accessing the stock via secondary venues, Elekta AB also trades in euros on platforms such as Tradegate, offering an additional access point outside its Swedish home market, although trading volumes are typically lower than on Nasdaq Stockholm.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

Elekta AB: core business model

Elekta AB focuses on developing and supplying radiation therapy hardware and oncology software, with revenues largely generated from sales of treatment systems and recurring service and software contracts to cancer care providers worldwide.

What banks and research houses say about Elekta AB

The SB1 Markets note summarized by MarketScreener on 05/29/2026 provides one of the latest explicit rating updates for Elekta AB, where the broker reaffirmed its Neutral stance while lowering the price target to SEK 57 from SEK 61, pointing to the need for stronger sales growth to underpin a higher valuation. This places SB1 Markets slightly below the MarketScreener-reported average target of SEK 60.50 as of 05/29/2026, implying that the broker is more conservative than the overall analyst consensus on Elekta AB at that date.

According to the same MarketScreener analyst overview as of 05/29/2026, Elekta AB’s consensus rating is broadly balanced, and the average target around SEK 60.50 sits meaningfully above the last quoted price of SEK 53.70, suggesting some expectation of fundamental improvement among covering analysts, even if opinions differ on the speed and reliability of margin expansion and revenue acceleration. No recent target changes from major Swedish houses such as SEB or Handelsbanken were flagged in that specific overview, but the combined effect of SB1 Markets’ more cautious target and the ongoing portfolio work by Pareto underscores that Nordic research remains actively engaged in valuing Elekta AB within the Swedish listed healthcare space.

Conclusion

The latest SB1 Markets report, with its Neutral rating, reduced SEK 57 price target, and call for better sales growth, provides a fresh analyst signal for Elekta AB alongside the removal of a disclosed short position by Schonfeld Strategic Advisors and the stock’s inclusion in a Pareto Swedish portfolio for June 2026. Together, these data points frame how Nordic market participants currently regard Elekta AB within the Swedish healthcare sector, balancing execution risks against potential operational improvement and the existing consensus target of around SEK 60.50. Investors following Elekta AB on Nasdaq Stockholm or via secondary European venues can use these inputs to contextualize daily price moves within a broader blend of valuation views, positioning changes, and expectations for top-line momentum.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.